PMID- 37364568
OWN - NLM
STAT- MEDLINE
DCOM- 20231108
LR  - 20231109
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 28
IP  - 11
DP  - 2023 Nov 2
TI  - Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung 
      Cancer.
PG  - 969-977
LID - 10.1093/oncolo/oyad182 [doi]
AB  - BACKGROUND: The survival benefits and adverse effects of pembrolizumab 2 mg/kg 
      intravenously (IV) every 3 weeks (Q3W) in advanced non-small lung cancer (NSCLC) 
      are well documented in the literature. Based on pharmacokinetic models, a 
      pembrolizumab 4 mg/kg IV every 6 weeks (Q6W) dosing regimen is also approved in 
      some countries. To date, there is no direct comparison in the literature between 
      these 2 regimens in advanced NSCLC. METHODS: This retrospective study included 80 
      patients with advanced NSCLC who received pembrolizumab monotherapy 4 mg/kg Q6W 
      between March 1, 2020 and December 31, 2021 and 80 patients with advanced NSCLC 
      who received pembrolizumab monotherapy 2 mg/kg Q3W between January 1, 2017 and 
      January 15, 2019 at Institut universitaire de cardiologie et de pneumologie de 
      Quebec (IUCPQ). The primary outcomes of this study were to compare overall 
      survival (OS), progression-free survival (PFS) as well as the occurrence and 
      severity of immune-mediated adverse events (AEs) in patients with advanced NSCLC 
      who received pembrolizumab Q6W vs Q3W. Data cutoff date was December 15, 2022. 
      RESULTS: Median follow-up was 14.5 +/- 8.6 months in the Q6W group and 18.3 +/- 19.6 
      months in the Q3W group. Median PFS was 6.9 months (CI 95% 5.0-10.7) in the Q6W 
      group vs 8.9 months (CI 95% 5.6-14.1) in the Q3W group (adjusted HR 1.27 (CI 95% 
      0.85-1.89), P = .25). Median OS was not reached in the Q6W group vs 20.5 months 
      (CI 95% 13.7-29.8) in the Q3W group (adjusted HR 0.80 (CI 95% 0.50-1.29), P = 
      .36). Immune-mediated AEs of grade >/= 3 occurred in 18% of patients in the Q6W 
      group and in 19% of those in the Q3W group. CONCLUSIONS: In this unicentric 
      retrospective study, the pembrolizumab Q6W dosing regimen was comparable to the 
      Q3W in terms of OS, PFS, and toxicity.
CI  - (c) The Author(s) 2023. Published by Oxford University Press.
FAU - Dube-Pelletier, Maude
AU  - Dube-Pelletier M
AD  - Institut universitaire de cardiologie et de pneumologie de Quebec, Universite 
      Laval, Quebec, Canada.
FAU - Labbe, Catherine
AU  - Labbe C
AD  - Institut universitaire de cardiologie et de pneumologie de Quebec, Universite 
      Laval, Quebec, Canada.
FAU - Cote, Jimmy
AU  - Cote J
AD  - Institut universitaire de cardiologie et de pneumologie de Quebec, Universite 
      Laval, Quebec, Canada.
FAU - Pelletier-St-Pierre, Audrey-Ann
AU  - Pelletier-St-Pierre AA
AD  - Institut universitaire de cardiologie et de pneumologie de Quebec, Universite 
      Laval, Quebec, Canada.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - DPT0O3T46P (pembrolizumab)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - *Lung Neoplasms
MH  - Retrospective Studies
MH  - Antibodies, Monoclonal, Humanized
PMC - PMC10628563
OTO - NOTNLM
OT  - advanced non-small cell lung cancer
OT  - pembrolizumab 2 mg/kg every 3 weeks
OT  - pembrolizumab 4 mg/kg every 6 weeks
COIS- Catherine Labbe has received honoraria from Amgen, AstraZeneca, Brystol-Myers 
      Squibb, Merck, Pfizer, and Roche. She has also received payment for expert 
      testimony from Jazz Pharmaceuticals, Pfizer, and Roche. She has also been on 
      advisory boards for Amgen, Astra Zeneca, Brystol-Myers Squibb, Jazz 
      Pharmaceuticals, LEO Pharma, Lilly, Merck, Novartis, Pfizer, Roche, and Sanofi 
      Genzyme. The other authors indicated no financial relationships.
EDAT- 2023/06/27 01:06
MHDA- 2023/11/08 06:43
PMCR- 2023/06/26
CRDT- 2023/06/26 18:33
PHST- 2023/03/07 00:00 [received]
PHST- 2023/06/01 00:00 [accepted]
PHST- 2023/11/08 06:43 [medline]
PHST- 2023/06/27 01:06 [pubmed]
PHST- 2023/06/26 18:33 [entrez]
PHST- 2023/06/26 00:00 [pmc-release]
AID - 7207982 [pii]
AID - oyad182 [pii]
AID - 10.1093/oncolo/oyad182 [doi]
PST - ppublish
SO  - Oncologist. 2023 Nov 2;28(11):969-977. doi: 10.1093/oncolo/oyad182.